Dogwood Therapeutics (DWTX) Total Liabilities (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Total Liabilities of $14.6 million for Q1 2026, up 2.45% year-over-year from $14.2 million in Q1 2025, and down 4.52% quarter-over-quarter from $15.3 million in Q4 2025.
Dogwood Therapeutics (DWTX) Total Liabilities (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Total Liabilities for 7 consecutive years, with $14.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 2.45% year-over-year to $14.6 million; the TTM figure through Mar 2026 stood at $14.6 million (up 2.45% YoY), while the FY2025 annual figure was $15.3 million, down 49.13% from the prior year.
- Total Liabilities declined to $14.6 million in Q1 2026 per DWTX's latest filing, from $15.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $30.0 million in Q4 2024 and bottomed at $358548.0 in Q4 2023.
- Historically, Total Liabilities has averaged $6.7 million across 5 years, with a median of $1.6 million in 2022.
- Annual changes were most pronounced in 2023 — Total Liabilities sank 72.6% — and 2024, when it surged 8274.67%.
- Dogwood Therapeutics' Total Liabilities stood at $1.0 million in 2022, then tumbled by 65.63% to $358548.0 in 2023, then soared by 8274.67% to $30.0 million in 2024, then plunged by 49.13% to $15.3 million in 2025, then retreated by 4.52% to $14.6 million in 2026.
- Business Quant data shows DWTX's Total Liabilities at $14.6 million in Q1 2026, $15.3 million in Q4 2025, and $14.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.58 Mn |
| Dec 31, 2025 | 15.27 Mn |
| Sep 30, 2025 | 14.61 Mn |
| Jun 30, 2025 | 14.15 Mn |
| Mar 31, 2025 | 14.24 Mn |
| Dec 31, 2024 | 30.03 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 500,076.00 |
| Mar 31, 2024 | 570,083.00 |
| Dec 31, 2023 | 358,548.00 |
| Sep 30, 2023 | 487,144.00 |
| Jun 30, 2023 | 520,032.00 |
| Mar 31, 2023 | 549,290.00 |
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 1.63 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 1.88 Mn |
| Dec 31, 2021 | 1.28 Mn |
| Sep 30, 2021 | 1.23 Mn |
| Jun 30, 2021 | 906,257.00 |